ETS transcription factors and targets in tumour invasion, angiogenesis and bone metastasis

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 1, 2001, Pages 87-107

  Seth, Arun ^a   Catzavelos, Charles ^b   Vary, Calvin ^c   Ascione, Richard ^d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Centre for Molecular Medicine   (United States)

^d Aphton Laboratory of Molecular Medicine   (United States)

Author keywords

breast cancer; cDNA microarray; ETS gene family; phosphorylation; signalling pathways; transcription factors

Indexed keywords

EID: 33846073145     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.5.1.87     Document Type: Review

References (144)

1. COLEMAN RE, SMITH P, RUBENS RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br. J. Cancer (1998) 77:336-340.
2. DOMCHEK SM, YOUNGER J, FINKELSTEIN DM, SEIDEN MV: Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer (2000) 89(2):363-368.
3. Cancer: Principles & Practice (4th Edition). Devita VTJ, Hellman S, Rosenberg SA (Ed.), JB Lippincott Company, Philadelphia, USA (1993).
4. FIDLER I: Molecular biology of cancer: invasion and metastasis. In: Cancer: Principles & Practice of Oncology (5thEdition). Devita V, JR., Hellman S, Rosenberg S (Eds.), Lippincott-Raven Publishers, Philadelphia, USA (1997):135-152.
5. DIEL IJ, SOLOMAYER EF, SEIBEL MJ et al: Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin. Cancer Res. (1999) 5:3914-3919.
6. GILLES F, RAES MB, STEHELIN D, VANDENBUNDER B, FAFEUR V: The c-ets-1 proto-oncogene is a new early-response gene differentially regulated by cytokines and growth factors in human fibroblasts. Exp. Cell Res. (1996) 222:370-378.
7. WALTREGNY D, BELLAHCENE A, DE LEVAL X, FLORKIN B, WEIDLE U, CASTRONOVO V: Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J. Bone Miner. Res. (2000) 15:834-843.
8. WESTERMARCK J, KAHARI VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEBJ. (1999) 13:781-92.
9. NIEDBALA MJ, STEIN M: Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed. Biochim. Acta (1991) 50:427-436.
10. MECHTCHERIAKOVA D, WLACHOS A, HOLZMULLER H, BINDER BR HOFER: E Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood (1999) 93:3811-3823.
11. RIUS C, SMITH JD, ALMENDRO N et al: Cloning of the promoter region of human endoglin,the target gene for hereditary hemorrhagic telangiectasia Type 1. Blood (1998) 92:4677-4690.
12. RODRIGO I, CATO AC, CANO A: Regulation of E-cadherin gene expression during tumor progression: the role of a new ETS-binding site and the E-pal element. Exp. Cell Res. (1999) 248:358-371.
13. VALTER MM, HUGEL A, HUANG HJ, CAVENEE WK, WIESTLER OD, PIETSCH T: Expression of the ETS1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res. (1999) 59:5608-5614.
14. CIRILLO G, CASALINO L, VALLONED, CARACCIOLO A, DE CESARE D, VERDE P: Role of distinct mitogen-activated protein kinase pathways and cooperation between ETS2, ATF-2 and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate. Mol. Cell Biol. (1999) 19:6240-6252.
15. DITTMER J, PISE-MASISON CA, CLEMENS KE, CHOI KS, BRADY JN: Interaction of human T-cell lymphotropic virus Type ITax,ETS1 and Sp1 in transactivation of the PTHrPP2 promoter.J.Biol. Chem. (1997) 272:4953-4958.
16. IM YH, KIM HT, LEE C et al.: EWS-FLI1, EWS-ERG and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta Type II receptor gene. Cancer Res. (2000) 60:1536-1540.
17. KARPERIEN M, FARIH-SIPS H, LOWIK CW, DE LAAT SW, BOONSTRA J, DEFIZE LH: Expression of the parathyroid hormone-related peptide gene in retinoic acid-induced differentiation: involvement of ETS and Sp1. Mol. Endocrinol. (1997) 11:1435-1448.
18. TSAI EY, FALVO JV, TSYTSYKOVA AV et al.: A lipopolysaccharide-specific enhancer complex involving ETS, Elk-1, Sp1 and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol. Cell Biol. (2000) 20:6084-6094.
19. XIE XQ, PARDALI E, HOLM M, SIDERAS P, GRUNDSTROM T: AML and ETS proteins regulate the I alpha1 germ-line promoter. Eur. J. Immunol. (1999) 29:488-498.
20. KIM YW, PARK YK, LEE J, KO SW, YANG MH: Expression of osteopontin and osteonectin in breast cancer. J. Korean Med. Sci. (1998) 13:652-657.
21. PAPAS TS, BHAT NK, SPYROPOULOS DD et al.: Functional relationships among ETS gene family members. Leukemia (1997) 3 (Suppl 11):557-566.
22. DONALDSON LW, PETERSEN JM, GRAVES BJ, MCINTOSH LP: Solution structure of the ETS domain from murine ETS1: a winged helix-turn-helix DNA binding motif. EMBOJ. (1996) 15:125-134.
23. ITO Y: Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells (1999) 4:685-696.
24. SATO M, MORII E, KOMORI T et al: Transcriptional regulation of osteopontin gene in vivo by PEBP2al-phaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene (1998) 17:1517-1525.
25. ASCIONE A, THOMPSON D, THOMAS Ret al: Influence of nucleotides flanking the-GGAA-core sequence on ETS1 and ETS2 DNA-binding activity and the mechanism of ETS1 autoregulation. Int. J. Oncol. (1992) 1:631-637.
26. VENANZONI MC, ROBINSON LR, HODGE DR, KOLA I, SETH A: ETS1 and ETS2 in p53 regulation: spatial separation of Ets-binding sites (EBS) modulate protein: DNA interaction. Oncogene (1996) 12:1199-1204.
27. GIOVANE A, PINTZAS A, MAIRA SM, SOBIESZCZUK P, WASYLYK B: Net, a new ETS transcription factor that is activated by Ras. GenesDev. (1994) 8:1502-1513.
28. WASYLYK B, HAGMAN J, GUTIERREZ-HARTMANN A: ETS transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem. Sci. (1998) 23:213-216.
29. COFFER P, DE JONGE M, METTOUCHI A, BINETRUY B, GHYSDAEL J, KRUIJER W: junB promoter regulation: Ras mediated transactivation by c-ETS1 and c-ETS2. Oncogene (1994) 9:911-921.
30. FOWLES LF, MARTIN ML, NELSEN L et al: Persistent activation of mitogen-activated protein kinases p42 and p44 and ETS2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling. Mol. Cell Biol. (1998) 18:5148-5156.
31. MCCARTHY SA, CHEND, YANGBS et al.: Rapid phosphorylation of ETS2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol. Cell Biol. (1997) 17:2401-2412.
32. MURAKAMI K, MAVROTHALASSITIS G, BHAT NK, FISHER RJ, PAPAS TS: Human ERG2 protein is a phosphorylated DNA-binding protein-a distinct member of the ETS family. Oncogene (1993) 8:1559-1566.
33. BEUG H, VON KIRCHBACH A, DODERLEIN G, CONSCIENCE JF, GRAF T: Chicken hematopoietic cells transformed by seven strains of defective avian leukemia viruses display three distinct phenotypes of differentiation. Cell (1979) 18:375-390.
34. LEPRINCE D, DUTERQUE-COQUILLAUD M, LI RP et al.: Alternative splicing within the chicken c-ets-1 locus: implications for transduction within the E26 retrovirus of the c-ets proto-oncogene. J. Virol. (1988) 62:3233-3241.
35. HART AH, CORRICK CM, TYMMS MJ, HERTZOG PJ, KOLA I: Human ERG is a proto-oncogene with mitogenic and transforming activity. Oncogene (1995) 10:1423-1430.
36. SETH A, PAPAS TS: The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. Oncogene (1990) 5:1761-1767.
37. SETH A, WATSON DK, BLAIR DG, PAPAS TS: c-ETS2 protooncogene has mitogenic and oncogenic activity. Proc. Natl. Acad. Sci. USA (1989) 86:7833-7837.
38. MAO X, MIESFELDT S, YANG H, LEIDEN JM, THOMPSON CB: The FLI1 and chimeric EWS-FLI1 oncoproteins display similar DNAbinding specificities. J. Biol. Chem. (1994) 269:18216-11222.
39. MAY WA, LESSNICK SL, BRAUN BS et al.: The Ewing's sarcoma EWS/FLI1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI1. Mol. Cell Biol. (1993) 13:7393-7398.
40. DELATTRE O, ZUCMAN J, PLOUGASTEL B et al.: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 359:162-165.
41. SORENSEN PH, LESSNICK SL, LOPEZ-TERRADA D, LIU XF, TRICHE TJ, DENNY CT: A second Ewing's sarcoma translocation, t(21;22), fuses the EWSgene to another ETS-family transcription factor, ERG. Nature Genet (1994) 6:146-151.
42. PETER M, COUTURIER J, PACQUEMENT H et al: Anew member of the ETS family fused to EWS in Ewing tumors. Oncogene (1997) 14:1159-1164.
43. CARROLLO M, TOMASSON MH, BARKER GF, GOLUB TR, GILLILAND DG: The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta Rkinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA (1996). 93:14845-14850.
44. GOLUB TR, BARKER GF, LOVETT M, GILLILAND DG: Fusion of PDGFreceptor beta to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 77:307-316.
45. CALMELS TP, MATTOT V, WERNERT N, VANDENBUNDER B, STEHELIN D: Invasive tumors induce c-ETS1 transcription factor expression in adjacent stroma. Biol. Cell (1995) 84:53-61.
46. WERNERT N, GILLES F, FAFEUR V, BOUALI F, RAES MB, PYKE C: Stromal expression of c-ETS1 transcription factor correlates with tumor invasion. Cancer Res (1994) 54:5683-5688.
47. NAITO S, SHIMIZU K, NAKASHIMA M et al: Overexpression of ETS1 transcription factor in angiosarcoma of the skin. Pathol. Res. Pract. (2000) 196:103-109.
48. NATHAN, C. AND M. SPORN: Cytokines in context. J. Cell Biol. (1991) 113:981-986.
49. RIFKIN DB, MOSCATELLI D: Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol. (1989) 109:1-6.
50. TAKEYAMA H, WAKAMIYA N, OHARA C, ARTHUR K, NILOFF J, KUFE D et al: Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. (1991) 51:4476-4480.
51. NAKAYAMA T, ITO M, OHTSURU A : Expression of the ETS1 proto-oncogene in human thyroid tumor. Mod. Pathol. (1999) 12:61-8.
52. RAOUF A, LI V, KOLA I, WATSON DK, SETH A: The ETS1 proto-oncogene is upregulated by retinoic acid: characterization of a functional retinoic acid response element in the ETS1 promoter. Oncogene (2000) 19:1969-1974.
53. OETTGEN P, FINGER E, SUN Z et al: PDEF, a novel prostate epithelium-specific ETS transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J. Biol. Chem. (2000) 275:1216-1225.
54. LIU AY, COREY E, VESSELLA RL et al.: Identification of differentially expressed prostate genes: increased expression of transcription factor ETS2 in prostate cancer. Prostate (1997) 30:145-153.
55. MONTE D, BAERT JL, LAGET MP et al: Transcription factors of the PEA3 group in mammary cancer. Ann. Endocrinol (1995) 56:547-551.
56. DE LAUNOIT Y, BAERT JL, CHOTTEAU A et al: Structure-function relationships of the PEA3 group of Ets-related transcription factors. Biochem. Mol. Med. 1997 61:127-135.
57. DE LAUNOIT Y, CHOTTEAU-LELIEVRE A, BEAUDOIN C et al.: The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv. Exp. Med. Biol. (2000) 480:107-116. (In Process).
58. WATABET, YOSHIDAK, SHINDOHM et al: The ETS1 and ETS2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int. J. Cancer (1998) 77:128-137.
59. KAYA M, YOSHIDA K, HIGASHINO F, MITAKA T, ISHII S, FUJINAGA K: A single ETS-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene (1996) 12:221-227.
60. SAPI E, FLICK MB, RODOV S, KACINSKI BM: ETS2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res. (1998)58:1027-1033.
61. BENZ CC, O'HAGAN RC, RICHTER B et al: HER2/Neu and the ETS transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene (1997)15:1513-1525.
62. CHIANG SY, BURLI RW, BENZ CC et al: Targetingthe ETS binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J. Biol. Chem. (2000) 275:24246-24254.
63. GALANG CK, GARCIA-RAMIREZ J, SOLSKI PA et al: Oncogenic Neu/ErbB-2 increases ETS, AP-1 and NF-KB-dependent gene expression and inhibiting ETS activation blocks Neu-mediated cellular transformation.J. Biol. Chem. (1996) 271:7992-7998.
64. O'HAGAN RC, HASSELL JA: The PEA3 ETS transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene (1998) 16:301-310.
65. BAERT JL, MONTE D, MUSGROVE EA et al: Expression of the PEA3 group of Ets-related transcription factors in human breast-cancer cells. Int. J. Cancer (1997) 70:590-597.
66. XING X, WANG SC, XIA W, ZOU Y, SHAO R, KWONG KY: The ETS protein PEA3 suppresses HER-2/neu overex-pression and inhibits tumorigenesis. Nature Med. (2000) 6:189-195.
67. HANZAWA M, SHINDOH M, HIGASHINO F et al: Hepato-cyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis (2000) 21:1079-1085.
68. FERTI-PASSANTONOPOULOU A, PANANI AD, RAPTIS S: Preferential involvement of 11q23-24 and 11p15 in breast cancer. Cancer Genet. Cytogenet. (1991) 51:183-188.
69. TYMMS MJ, NG AY, THOMAS RS et al: Anovel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene (1997) 15:2449-2462.
70. SEMENTCHENKO VI, WATSON DK: Ets target genes: past,present and future. Oncogene (2000) 19:6533-6548.
71. CHU YW, YANG PC, YANG SC, SHYU YC, HENDRIX MJ, WU R, WU CW: Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Bio.l (1997) 17:353-360.
72. SCHALLER G, FUCHS I, PRITZE W ET AL.: Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin. Cancer Res. (1996) 2:1879-1885.
73. CROWE DL, BROWN TN: Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion. Neoplasia (1999) 1:368-372.
74. ZEIGLER ME, CHI Y, SCHMIDT T, VARANI J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell Physiol. (1999) 180:271-284.
75. GOLD LI: The role for transforming growth factor-pi (TGF-P) in human cancer. Crit. Rev. Oncog. (1999) 10:303-360.
76. HAHM KB, CHO K, LEE C et al: Repression of the gene encoding the TGF-P Type IIreceptor is a major target of the EWS-FLI1 oncoprotein [published erratum appears in Nature Genet. (1999) 23(4):481]. NatureGenet. (1999) 23:222-227.
77. DU B, FU C, KENT KC et al: Elevated EGR1 in human atherosclerotic cells transcriptionally represses the TGF-P Type II receptor. J. Biol. Chem. (2000) 275 (50):39039-39047.
78. ROBINSON L, PANAYIOTAKIS A, PAPAS TS, KOLA I, SETH A: ETS target genes: identification of EGR1 as a target by RNA differential display and whole genome PCR techniques. Proc. Natl. Acad. Sci. USA (1997) 94:7170-7175.
79. CHANG J, LEE C, HAHM KB, YI Y, CHOI SG, KIM SJ: Over-expression of ERT(ESX/ESE-1/ELF3), an ETS-related transcription factor, induces endogenous TGF-P Type II receptor expression and restores the TGF-P signaling pathway in Hs578t human breast cancer cells. Oncogene (2000) 19:151-14.
80. FENRICK R, WANG L, NIP J et al.: TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol. Cell Biol. (2000) 20:5828-5839.
81. SHAO N, CHAIY, CUIJQ, WANG N, AYSOLAK, REDDYES, RAO VN: Induction of apoptosis by Elk-1 and deltaElk-1 proteins. Oncogene (1998) 17:527-532.
82. KLEINBAUM LA, DUGGAN C, FERREIRA E, COFFEY GP, BUTTICE G, BURTON FH: Human chromosomal localization, tissue/tumor expression and regulatory function of the ETSfamily gene EHF. Biochem. Biophys. Res. Commun. (1999) 264:119-126.
83. LIOTTA LA: Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. (1986) 46:1-7.
84. KOHN EC, LIOTTA LA: Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. (1995) 55:1856-1862.
85. LIOTTA LA, STEEG PS, STETLER-STEVENSON WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 64:327-336.
86. RUTTER JL, MITCHELL TI, BUTTICE G et al: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an ETS binding site and augments transcription. Cancer Res. (1998) 58:5321-5325.
87. WESTERMARCK J, SETH A, KAHARI VM: Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene (1997) 14:2651-2660.
88. GARBETT EA, REED MW, STEPHENSON TJ, BROWN NJ: Proteolysis in human breast cancer. Mol. Pathol. (2000) 53:99-106.
89. UEDA M, FUJII H, YOSHIZAWA K, TERAI Y, KUMAGAI K, UEKI K et al: Effects of EGFand TGF-OCon invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells. Invasion Metastasis (1998) 18:176-183.
90. FAFEUR V, TULASNE D, QUEVA C et al. The ETS1 transcription factor is expressed during epithelial-mesenchymal transitions in the chick embryo and is activated in scatter factor-stimulated MDCK epithelial cells. Cell Growth Differ. (1997) 8:655-665.
91. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353-364.
92. INGBERDE, FOLKMAN J: How does extracellular matrix control capillary morphogenesis? Cell (1989) 58:803-805.
93. WOODHOUSE EC, CHUAQUI RF, LIOTTA LA: General mechanisms of metastasis. Cancer (1997) 80:1529-1537.
94. DIETERLEN-LIEVRE F, PARDANAUD L, GODIN I, GARCIA-PORRERO J, CUMANO A, MARCOS M: Developmental relationships between hemopoiesis and vasculo-genesis. CR Acad. Sci. III (1993) 316:892-901.
95. VANDENBUNDER B, PARDANAUD L, JAFFREDO T, MIRABEL MA, STEHELIN D: Complementary patterns of expression of c-ets 1, c-myb and c-myc in the blood-forming system of the chick embryo. Development (1989) 107:265-274.
96. WERNERT N, RAES MB, LASSALLE P et al: c-ETS1proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am.J. Pathol (1992) 140:119-127.
97. PLATE KH, BREIER G, MILLAUER B, ULLRICH A, RISAU W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. (1993) 53:5822-5827.
98. WAKIYA K, BEGUE A, STEHELIN D, SHIBUYA M: A cAMP response element and an ETS motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene.J. Biol. Chem. (1996) 271:30823-30828.
99. IWASAKA C, TANAKA K, ABE M, SATO Y: ETS1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells.J. Cell Physiol. (1996) 169:522-5231.
100. CHEN Z, FISHER RJ, RIGGS CW, RHIM JS, LAUTENBERGER JA: Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res. (1997) 57:2013-2019.
101. EDEL MJ: The ETS-related factor TEL is regulated by angiogenic growth Factor VEGF in HUVE-cells. AntiCancer Res. (1998) 18:4505-4509.
102. SATO Y: Transcription factor ETS1 as a molecular target for angiogenesis inhibition. Hum. Cell (1998) 11:207-214.
103. KITANGE G, KISHIKAWA M, NAKAYAMA T, NAITO S, ISEKI M, SHIBATA S: Expression of the ETS1 proto-oncogene correlates with malignant potential in human astrocytic tumors. Mod. Pathol. (1999) 12:618-626.
104. KITANGE G, SHIBATA S, TOKUNAGA Y et al: ETS1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Lab. Invest. (1999) 79:407-416.
105. MATTOT V, VERCAMER C, SONCIN F, FAFEUR V, VANDENBUNDER B: Transcription factors of the ETS family and morphogenesis of the vascular tree. J. Soc. Biol. (1999) 193:147-153.
106. SCHLAEGER TM, BARTUNKOVA S, LAWITTS JA, TEICHMANN G, RISAU W, DEUTSCH U et al.: Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc. Natl. Acad. Sci. USA (1997) 94:3058-3063.
107. DUBE A, AKBARALI Y, SATO TN, LIBERMANN TA, OETTGEN P: Role of the ETS transcription factors in the regulation of the vascular-specific TIE2gene. Circ. Res. (1999) 84:1177-1185.
108. ALTOMONTE M, MONTAGNER R, FONSATTI E et al.: Expression and structural features of endoglin (CD105), a transforming growth factor|51 and [33 binding protein, in human melanoma. Br. J. Cancer (1996) 74:1586-1591.
109. BODEY B, BODEY B, JR., SIEGEL SE, KAISER HE: Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. AntiCancer Res. (1998) 18:2701-2710.
110. BODEY B, BODEY B, JR., SIEGEL SE, KAISER HE: Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. AntiCancer Res. (1998) 18:3621-3628.
111. BODEY B, BODEY B Jr, SIEGEL SE, KAISER HE: Upregula-tion of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. AntiCancer Res. (1998) 18:1485-1500.
112. LETAMENDIA A, LASTRES P, ALMENDRO N et al.: Endoglin, a component of the TGF-|5 receptor system, is a differentiation marker of human choriocarcinoma cells. Int.J. Cancer (1998) 76:541-546.
113. GUERRERO-ESTEO M, LASTRES P, LETAMENDIA A et al.: Endoglin over-expression modulates cellular morphology, migration and adhesion of mouse fibroblasts. Eur.J. Cell Biol. (1999) 78:614-623.
114. SHARP JA, SUNG V, SLAVIN J, THOMPSON EW, HENDERSON MA: Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab. Invest. (1999) 79:869-877.
115. JACOB K, WEBBER M, BENAYAHU D, KLEINMAN HK: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. (1999) 59:4453-4457.
116. VARY C, LI V, RAOUF A, KOLA I, SETH A: Involvement of ETS1 and ETS2 transcription factors and their targets in osteoblastfunction. Exp. Cell Res. (2000) 257:213-222.
117. BELLAHCENE A, CASTRONOVO V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am.J. Pathol. (1995) 146:95-100.
118. KOLA I, BROOKES S, GREEN AR et al.: The ETS1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc. Natl. Acad. Sci. USA (1993) 90:7588-7592.
119. LANGMAN J: Skeletal system and ossification. In: Medical Embryology. Langman J (Ed.). Williams and Wilkins, Baltimore, USA (1975):137-153.
120. OWEN TA, ARONOW M, SHALHOUB V, BARONE LM, WILMING L, TASSINARI MS et al: Progressive development of the rat osteoblast phenotype in vitro: reciprocalrelationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J. Cell Physiol. (1999) 143:420-430.
121. OWENS M: Cell population kinetics of an osteogenic tissue.J. Cell Biol. (1963) 19:19-40.
122. ARONOW MA, GERSTENFELD LC, OWEN TA, TASSINARI MS, STEIN GS, LIAN JB: Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J. Cell Physiol. (1990) 143:213-221.
123. BORTELL R, BARONE LM, TASSINARI MS, LIAN JB, STEIN GS: Gene expression during endochondral bone development: evidence for coordinate expression of transforming growth factor |51 and collagen Type I. J. CellBiochem. (1990) 44:81-91.
124. CARRINGTON JL, ROBERTS AB, FLANDERS KC, ROCHE NS, REDDI AH: Accumulation, localization and compartmentation of transforming growth factor pi during endochondral bone development. J. Cell Biol. (1988) 107:1969-1975.
125. CENTRELLA M, MCCARTHY TL, CANALIS E: Skeletal tissue and transforming growth factor p. FASEB J. (1988) 2:3066-3073.
126. GLIMCHER MJ: Mechanism of calcification: role of collagen fibrils and collagen-phosphoprotein complexes in vitro and in vivo. Anat. Rec. (1989) 224:139-153.
127. NOMURA S, HOGAN BL, WILLS AJ, HEATH JK, EDWARDS DR: Developmental expression of tissue inhibitor of metalloproteinase (TIMP) RNA. Development (1989) 105:575-583.
128. NOMURA S, WILLS AJ, EDWARDS DR, HEATH JK, HOGAN BL: Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization.J. Cell Biol. (1988) 106:441-450.
129. STEIN GS, LIAN JB, GERSTENFELD LG, SHALHOUB V, ARONOW M, OWEN T et al: The onset and progression of osteoblast differentiation is functionally related to cellular proliferation. Connect. TissueRes. (1989) 20:3-13.
130. MAROULAKOU IG, PAPAS TS, GREEN JE: Differential expression of ETS1 and ETS2proto-oncogenes during murine embryogenesis. Oncogene (1994) 9:1551-1565.
131. SUMARSONO SH, WILSON TJ, TYMMS MJ et al: Down's syndrome-like skeletal abnormalities in ETS2 transgenic mice. Nature (19960 379:534-537.
132. DITTMER J, GITLIN SD, REID RL, BRADY JN: Transactiva-tion of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus Type I Tax1: evidence for the involvement of transcription factor ETS1.J. Virol (1993) 67:6087-6095.
133. GOLTZMAN D, KARAPLIS AC, KREMER R, RABBANI SA: Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer (2000) 88:2903-2908.
134. TONDRAVI MM, MCKERCHER SR, ANDERSON K et al: Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature (1997) 386:81-84.
135. JANOWSKA-WIECZOREK A, MARQUEZ LA, MATSUZAKIA et al.: Expression of matrix metalloproteinases (MMP-2 and-9) and tissue inhibitors of metalloproteinases (TIMP-1 and-2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. (1999) 105:402-411.
136. JANOWSKA-WIECZOREKA,MARQUEZ LA, NABHOLTZJM et al.: Growth factors and cytokines upregulate gelati-nase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood (1999) 93:3379-3390.
137. KOENEMAN KS, YEUNG F, CHUNG LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate (1999) 39:246-261.
138. ZHAU HE, LI CL, CHUNG LW: Establishment of human prostate carcinoma skeletal metastasis models. Cancer (2000) 88:2995-3001.
139. FESTUCCIA C, BOLOGNA M, GRAVINA GL et al.: Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int. J. Cancer (1999) 81:395-403.
140. FESTUCCIA C, GIUNCIUGLIO D, GUERRA F et al.: Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol. Res. (1999) 11:17-31.
141. POSADA R, PETTOELLO-MANTOVANI M, SIEWEKE M, GRAF T, GOLDSTEIN H: Suppression of HIV Type 1 ReplicationbyaDominant-Negative Ets-1 Mutant.AIDS Res. Hum. Retroviruses (2000) 16(18):1981-1989.
142. ATHANASIOU M, LEGALLIC L, WATSON DK, BLAIR DG, MAVROTHALASSITIS G: Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids. Cancer Gene Ther. (2000) 7(8):1188-1195.
143. LOGAN SK, GARABEDIAN MJ, CAMPBELL CE, WERB Z: Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and ETS1 transcription factors. J. Biol. Chem. (1996) 271:774-782.
144. WATSON SA, MORRIS TM, PARSONS SL, STEELE RJ, BROWN PD: Therapeutic effect of the matrix metallo-proteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br. J. Cancer (1996) 74(9):1354-1358.